1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D048588:Benzoxazines; D001682:Biological Availability; D005260:Female; D006801:Humans; D007700:Kinetics; D015394:Molecular Structure; D007752:Obstetric Labor, Premature / Q000188:drug therapy; D010078:Oxazines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D010121:Oxytocin / Q000037:antagonists & inhibitors*; D010880:Piperidines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D011247:Pregnancy; D051381:Rats; D018045:Receptors, Oxytocin / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000378:metabolism; D014590:Uterine Contraction / Q000187:drug effects
D065092:Antidiuretic Hormone Receptor Antagonists; D048588:Benzoxazines; C096766:L 371257; D010078:Oxazines; D010880:Piperidines; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D010121:Oxytocin